Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.37 |
| ▸ | RELA | Q04206 | 4/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147501 | 0.87 | CTSK (0.43) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL25872149 | 0.84 | CTSK (0.39) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL12026396 | 0.81 | CTSK (0.50) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL17987960 | 0.80 | CTSK (0.42) | CTSKNFKB1NFKB2RELACA1 | |
| SCHEMBL18484241 | 0.80 | CTSK (0.42) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL20147316 | 0.79 | CTSK (0.44) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL20069569 | 0.77 | CTSK (0.42) | CTSKNFKB1NFKB2RELAHRH3 | |
| SCHEMBL2189808 | 0.77 | PDE4B (0.46) | CTSKNFKB1NFKB2RELACA1 | |
| SCHEMBL744174 | 0.77 | CTSK (0.40) | CTSKNFKB1NFKB2RELACA1 | |
| SCHEMBL3824957 | 0.77 | CTSK (0.40) | CTSKNFKB1NFKB2RELACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CTSK 3569/4885NFKB1 1862/4885NFKB2 2573/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CTSK 3569/4885NFKB1 1862/4885NFKB2 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.